| BID | 193.43 | ASK | 193.65 | ||
| Open | 196.49 | Previous Close | 196.76 | ||
| Pre-Market | 197.00 | After-Market | - | ||
| 0.24 0.12% | - - |
| Target Price | 255.87 | Analyst Rating | Strong Buy 1.28 | |
| Potential % | 32.06 | Finscreener Ranking | ★ 41.55 | |
| Insiders Trans % 3/6/12 mo. | -/-/-33 | Value Ranking | + 34.97 | |
| Insiders Value % 3/6/12 mo. | -/-/-96 | Growth Ranking | ★★★ 51.42 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-/-96 | Income Ranking | — - | |
| Price Range Ratio 52W % | 31.16 | Earnings Rating | Sell | |
| Market Cap | 36.03B | Earnings Date | 26th Apr 2023 | |
| Alpha | 0.01 | Standard Deviation | 0.09 | |
| Beta | 1.33 |
Today's Price Range 192.88196.87 | 52W Range 165.75254.94 | 5 Year PE Ratio Range 16.00199.70 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 0.76% | ||
| 1 Month | -6.74% | ||
| 3 Months | -3.14% | ||
| 6 Months | 3.22% | ||
| 1 Year | -14.05% | ||
| 3 Years | 114.64% | ||
| 5 Years | 93.13% | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 4.22 | |||
ROE last 12 Months | 21.15 | |||
ROA (5Y Avg) | 1.16 | |||
ROA last 12 Months | 4.90 | |||
ROC (5Y Avg) | 4.06 | |||
ROC last 12 Months | 8.16 | |||
Return on invested Capital Q | 2.02 | |||
Return on invested Capital Y | 2.13 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 1.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 33.40 | ||||
| 7.13 | ||||
| 3.63 | ||||
| 16.50 | ||||
| 223.10 | ||||
| 15.38 | ||||
| -3.04 | ||||
| 30.51 | ||||
| 49.44B | ||||
| Forward PE | 19.14 | |||
| PEG | 3.44 |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 0.90 | ||||
| 0.70 | ||||
| 2.37 | ||||
| 4.80 | ||||
| Leverage Ratio | 4.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 34.70 | ||||
| 12.90 | ||||
| 20.10 | ||||
| 4.70 | ||||
| 8.10 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 10.67B | ||||
| 57.45 | ||||
| 8.82 | ||||
| 9.85 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q04 2022 | 2.54 | 2.54 | 0.00 |
| Q03 2022 | 2.19 | 2.23 | 1.83 |
| Q02 2022 | 2.21 | 2.25 | 1.81 |
| Q01 2022 | 2.27 | 2.34 | 3.08 |
| Q04 2021 | 2.25 | 2.42 | 7.56 |
| Q03 2021 | 1.99 | 2.02 | 1.51 |
| Q02 2021 | 1.92 | 1.94 | 1.04 |
| Q01 2021 | 1.70 | 2.05 | 20.59 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | 2.54 | -3.42 | Negative |
| 12/2022 FY | 9.35 | -0.53 | Negative |
| 3/2023 QR | 2.40 | -4.76 | Negative |
| 12/2023 FY | 10.02 | -5.74 | Negative |
| Next Report Date | 26th Apr 2023 |
| Estimated EPS Next Report | 2.21 |
| Estimates Count | 8 |
| EPS Growth Next 5 Years % | 9.70 |
| Volume Overview | |
|---|---|
| Volume | 610.40K |
| Shares Outstanding | 186.14K |
| Shares Float | 166.97M |
| Trades Count | 14.78K |
| Dollar Volume | 119.13M |
| Avg. Volume | 1.13M |
| Avg. Weekly Volume | 1.38M |
| Avg. Monthly Volume | 1.11M |
| Avg. Quarterly Volume | 893.11K |
IQVIA Holdings Inc. (NYSE: IQV) stock closed at 196.76 per share at the end of the most recent trading day (a 2.58% change compared to the prior day closing price) with a volume of 1.06M shares and market capitalization of 36.03B. Is a component of S&P 500, Russell 1000 indices and it is traded on NYSE exchange. The company belongs in the Medical Diagnostics & Research industry, Healthcare sector and employs 77000 people. IQVIA Holdings Inc. CEO is Ari Bousbib.
The one-year performance of IQVIA Holdings Inc. stock is -14.05%, while year-to-date (YTD) performance is -3.97%. IQV stock has a five-year performance of 93.13%. Its 52-week range is between 165.75 and 254.94, which gives IQV stock a 52-week price range ratio of 31.16%
IQVIA Holdings Inc. currently has a PE ratio of 33.40, a price-to-book (PB) ratio of 7.13, a price-to-sale (PS) ratio of 3.63, a price to cashflow ratio of 16.50, a PEG ratio of 2.32, a ROA of 4.90%, a ROC of 8.16% and a ROE of 21.15%. The company’s profit margin is 8.10%, its EBITDA margin is 20.10%, and its revenue ttm is $10.67 Billion , which makes it $57.45 revenue per share.
Of the last four earnings reports from IQVIA Holdings Inc., there were 3 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $2.21 for the next earnings report. IQVIA Holdings Inc.’s next earnings report date is 26th Apr 2023.
The consensus rating of Wall Street analysts for IQVIA Holdings Inc. is Strong Buy (1.28), with a target price of $255.87, which is +32.06% compared to the current price. The earnings rating for IQVIA Holdings Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
IQVIA Holdings Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
IQVIA Holdings Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 9.44, ATR14 : 6.63, CCI20 : -78.56, Chaikin Money Flow : 0.09, MACD : -7.10, Money Flow Index : 34.13, ROC : -10.90, RSI : 38.43, STOCH (14,3) : 22.34, STOCH RSI : 1.00, UO : 55.68, Williams %R : -77.66), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of IQVIA Holdings Inc. in the last 12-months were: Eric M. Sherbet (Sold 1 000 shares of value $230 000 )
IQVIA Holdings Inc.
IQVIA is the result of the 2016 merger of Quintiles, a leading global contract research organization, and IMS Health, a leading healthcare data and analytics provider. The Research & Development segment focuses primarily on providing outsourced late-stage clinical trials for pharmaceutical, device, and diagnostic firms. The Technology & Analytics segment provides aggregated information and technology services to clients in the healthcare industry, including pharmaceutical companies, providers, payers, and policymakers, as well as data and analytics capabilities for clinical trials, including virtual trials. The company also has a small contract sales business.
CEO: Ari Bousbib
Telephone: +1 919 998-2000
Address: 4820 Emperor Boulevard, Durham 27703, NC, US
Number of employees: 77 000
TipRanks News for IQV
Wed, 15 Feb 2023 05:13 GMT Analysts Conflicted on These Healthcare Names: IQVIA Holdings (IQV), Reata Pharmaceuticals (RETA) and Roivant Sciences (ROIV)
- TipRanks. All rights reserved.
